Pelthos Therapeutics (PTHS) announced that the first patient has been dosed in a Phase 1b/2a clinical trial evaluating CT2000 as a potential treatment for eye pain. Pelthos’ subsidiary Channel Pharmaceutical Corporation owns the rights to CT2000 and its NaV1.7 inhibitor pipeline and is conducting the clinical work through its Australian subsidiary.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTHS:
- Pelthos Therapeutics Inc trading resumes
- Pelthos Therapeutics Inc trading halted, volatility trading pause
- Pelthos Therapeutics price target raised to $62 from $60 at Oppenheimer
- Pelthos Highlights 2025 Results and Portfolio Expansion Progress
- Pelthos Therapeutics reports Q4 EPS ($6.87) vs. ($3.19) last year